: Quadrant Biosciences gets FDA approval for saliva-based COVID-19 test

/ / News

Quadrant Biosciences said late Wednesday it received an emergency approval from the Food and Drug Administration for a saliva-based COVID-19 test. The privately held Syracuse, N.Y.-based company developed the test along with State University of New York’s Upstate Medical University. Called the “Clarifi COVID-19” test, the diagnostic collects saliva with a swab and uses reagents to detect nucleic acid from SARS-CoV-2, the virus that causes COVID-19. The test is available for bulk purchases immediately by clinical laboratories for use at healthcare facilities, Quadrant said.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.